Structural binding site comparisons reveal Crizotinib as a novel LRRK2 inhibitor. Comput. Struct. Biotechnol. J., (19):3674--3681, Elsevier BV, June 2021. [PUMA: Binding Crizotinib; Drug LRRK2; Protein-ligand Structure-based interactions; repositioning; screening site;]
Structural comparative modeling of multi-domain F508del CFTR. Biomolecules, (12)3:471, MDPI AG, March 2022. [PUMA: VX-809; chaperones; comparative computational cystic discovery disease; drug fibrosis; folding modeling; pharmacological protein structure-based topic_lifescience]
Introduction to the BioChemical Library (BCL): An application-based open-source toolkit for integrated cheminformatics and machine learning in computer-aided drug discovery. Front. Pharmacol., (13):833099, Frontiers Media SA, February 2022. [PUMA: BCL; QSAR; biochemical cheminformatics; deep design; discovery; drug library; network; neural open-source topic_lifescience]
Targeting in silico GPCR conformations with ultra-large library screening for hit discovery. Trends Pharmacol. Sci., (44)3:150--161, Elsevier BV, March 2023. [PUMA: AlphaFold; GPCR; biased discovery; drug library ligands; structure-based topic_lifescience ultra-large]
Improving the modeling of extracellular ligand binding pockets in RosettaGPCR for conformational selection. Int. J. Mol. Sci., (24)9April 2023. [PUMA: Rosetta; RosettaGPCR; discovery; docking; drug homology ligand modeling; pocket refinement topic_lifescience]